Substitute for form 1449/PTO, based on PTO/SB/08A-000,008	Application Number	10/680,076
	Filing Date	October 6, 2003
INFORMATION DISCLOSURE	First Named Inventor	Bell et al.
	Art Unit	1614 1624
E San S	Examiner Name	Notaesigned COLEMAN
F. 100	Attorney Docket Number	36-02

PATENT DOCUMENTS

Examiner Initial*	Cite No.1	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Relevant Fig Relevant Fig (or entire doc	is, Lines, Where Passages or gures Appear cument unless therwise)
80		6,342,492	01/29/02	Bell	514	183
BC		6,335,339	01/01/02	Arenas et al.	514	245
BC		5,663,161	09/02/97	Bell	514	183
BC		5,565,562	10/15/96	Parker et al.	540	465
BC		2002/0019423	02/14/02	Bell	514	360

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T²
Br		WO96/025167	08/22/96			
BC		JP 08-27129	01/30/96			

NON-PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
BC		Bell, T.W. et al. (March 2002), "Specific CD4 Down-modulating Compounds with Potent Anti-HIV and HHV-7 Activity," Abstract, 15 th Intl. Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002	
BC		Chieco-Bianchi, L. et al. (1989), "CD4 modulation and inhibition of HIV- 1 infectivity induced by monosialoganglioside GM1 in vitro," AIDS 3:501-507	
BC		Chowdhury, I.H. et al. (1990), "The Phorbol Ester TPA Strongly Inhibits HIV-1-induced Synctia Formation but Enhances Virus Production: Possible Involvement of Protein Kinase C Pathway," Virology 176:126-132	
BC		Hoffman, T.L. et al. (1990), "Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein," Proc. Natl. Acad. Sci. USA 96 :6359-6364	

Examiner Signature	Brenda	Coleman	Date Considered	ept 29 2006
AFT VALABLE				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional).

2Applicant is to place a check mark here or "x" if English language Translation is attached.

Sheet 2 of 2

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B 10/680,076 **Application Number** October 6, 2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Bell et al. Notassigned COLEMAN STATEMENT BY APPLICANT Art Unit **Examiner Name** Attorney Docket Number 36-02

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BC		Kabat, D. et al. (1994), "Differences in CD4 Dependence for Infectivity of Laboratory-Adapted and Primary Patient Isolates of Human Immunodeficiency Virus Type 1," J. Virol. 68:2570-2577	
BC		Kolchinski, P. et al. (March 2001), "Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants," J. Virol. 75:2041-2050	
BC		Layne, S.P. et al. (<u>1990</u>), "HIV requires multiple gp120 molecules for CD4 mediated infection," Nature 346 :277-279	
BC	_	Neudorf, S. et al. (1989), "Expression of the CD4 Molecule of Acute Nonlymphocytic Leukemia (ANLL) Cell Lines," J. Clin. Lab. Anal. 3:312-315	
BC		Platt, E.J. et al. (1997), "Infectious Properties of Human Immunodeficiency Virus Type 1 Mutants with Distinct Affinities for the CD4 Receptor," J. Virol. 61:883-890	
BC		Schols, D. et al. (1989), "Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor," Proc. Natl. Acad. Sci. USA 86:3322-3326	
BC		Vermeire, K. et al. (January 2003), "The Anti-HIV Potency of Cyclotriazadisulfonamide Analogs is Directly Correlated with Their Ability to Down-Modulate the CD4 Receptor,"Mol. Pharmacol. 63 :203-210	
BC		Vermeire, K. et al. (October 2002), "CADA Inhibits Human Immunodeficiency Virus and Human Herpesvirus 7 Replication by Down-modulation of the Cellular CD4 Receptor," Virology 302: 342-353	
BC		Zhang, Y. et al. (<u>1999</u>), "Selective activity of various antiviral compounds-against-HHV-7-infection;" Antiviral-Res 43 :23-35	

					to server and	
I Examiner <)	()	Date		- ^	
	P1		Date	6	\sim	$\triangle M \triangle M$
Signature	1 neuda	A(0,000 000)	Considered	1000	~/~	2006
Oig.idtarc	9 3 -	-000/VCO-0	Considered	2011	٠١،	<u> </u>

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional).

2Applicant is to place a check mark here or "x" if English language Translation is attached.

10680076

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

INFORMATION BIOOL COURT			Filing	Filing Date			2003-10-06					
		TION DISCLOSE		First	Named	Inventor	Thor	homas Bell				
		NT BY APPLICATION OF STREET		Art U	nit			1624				
(1101 101	345111	ission under or or it	1.55)	Exam	iner Na	me	COL	EMAN, Brenda Lib	by			
				Attorr	Attorney Docket Number 36-02							
					U.S.	PATENTS						
Examiner Initial*	Examiner Cite Initial* Cite No Patent Number Kind Code1			Issue i	Issue Date Name of Particle Documents of Cited Doc			Rele		ges,Columns,Lines where evant Passages or Relevan ures Appear		
	1											
If you wish	h to a	dd additional U.S. Pate	nt citatio	n inform	nation pl	lease click	the A	dd button.				
			U.S.P	ATENT	APPLI	CATION P	UBLI	CATIONS				
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date			ted Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1											
If you wist	h to ac	dd additional U.S. Publi	shed Ap	plication	n citatio	n information	on ple	ease click the Add	butto	on.		
				FORE	GN PAT	ENT DOC	UME	NTS				
Examiner	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publicatio Date	n /	Name-of-Patented Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T5	
	1											
If you wist	h to ac	dd additional Foreign Pa	atent Do	cument	citation	informatio	n plea	ase click the Add	buttor	n		
			NON	-PATE	NT LITE	RATURE	DOC	JMENTS				
Examiner Initials*	Cite No	Include name of the ar (book, magazine, journ publisher, city and/or of	nal, seria	al, symp	osium,	catalog, et	of the	e article (when a te, pages(s), volu	ppropi ime-is	riate), title of the item sue number(s),	T 5	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10680076		
Filing Date		2003-10-06		
First Named Inventor Thor		nas Bell		
Art Unit		1624		
Examiner Name COL		EMAN, Brenda Libby		
Attorney Docket Number		36-02		

		Attorney booker Harribe	,61	30-02					
BCI	BELL, T.W., et al., Synthesis and Structure - Activity Relationship Studies of CD4 Down-Modulating Cyclotriazadisulfonamide (DADA) Analogues, J. Med. Chem. 2006, 49, 1291-1312. Published on Web 02/02/2006.								
If you wish to ac	dd additional non-patent	literature document citation inform	mation	please click the Add	button				
		EXAMINER SIGNAT	TURE						
Examiner Signa	ature Brenda	Coleman		Date Considered	Sept.	296	2006		
		red, whether or not citation is in considered. Include copy of this for					1		
Standard ST.3). 3 F	For Japanese patent document	at www.USPTO.GOV or MPEP 901.04. ² Es, the indication of the year of the reign of indicated on the document under WIPO s	of the Emp	peror must precede the se	erial number of	the patent do	ocument		